economy
February 4, 2026
Novo Nordisk CEO addresses U.S. headwinds after guidance shock
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.
TL;DR
- Discussion of Novo Nordisk's Q4 financial results.
- Focus on the increasing demand and adoption of obesity drugs.
- Strategies for navigating price pressures expected in 2026.
Continue reading the original article